Europe signs agreement for up to 200 million doses of Novavax's experimental COVID-19 shot

Shares of Novavax Inc. gained 9.8% in trading on Wednesday after the company said the European Commission will buy up to 200 million doses of its experimental COVID-19 vaccine. The deal covers an initial 100 million doses and the option to buy an additional 100 million doses through 2023. The company said it expects to complete its submission to E.U. regulators in the third quarter of this year. Novavax's stock has soared 87.8% so far this year, while the broader S&P 500 is up 17.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Europe signs agreement for up to 200 million doses of Novavax's experimental COVID-19 shot
Shares of Novavax Inc. gained 9.8% in trading on Wednesday after the company said the European Commission will buy up to 200 million doses of its experimental COVID-19 vaccine. The deal covers an initial 100 million doses and the option to buy an additional 100 million doses through 2023. The company said it expects to complete its submission to E.U. regulators in the third quarter of this year. Novavax's stock has soared 87.8% so far this year, while the broader S&P 500 is up 17.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.